Enliven Therapeutics, Inc. (ELVN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed on June 11, 2026, by Enliven Therapeutics, Inc. The filing discloses updated positive data from the Phase 1 ENABLE clinical trial evaluating ELVN-001 for chronic myeloid leukemia (CML) and key outcomes from an End-of-Phase 1 meeting with the U.S. Food and Drug Administration (FDA).
Key Clinical and Operational Metrics
The filing focuses on clinical trial progress rather than financial performance. No revenue, profit, cash flow, or debt metrics are provided in this document.
- Enrollment: 161 patients enrolled as of March 10, 2026, across dose levels of 10-240 mg daily.
- Patient Retention: 76% of patients remain on study with a median treatment duration of 35 weeks.
- Prior Treatment: 70% of patients received three or more prior unique tyrosine kinase inhibitors (TKIs); 23% received five or more.
- Efficacy (24 Weeks):
- Overall Phase 1b: 54% achieved Major Molecular Response (MMR); 22% achieved Deep Molecular Response (DMR).
- 80 mg QD Cohort: 61% achieved MMR; 30% achieved DMR.
- Safety: 6% of patients discontinued due to adverse events. Grade 3+ treatment-emergent adverse events occurred in 34% of patients overall, dropping to 24% at the 80 mg QD dose.
Material Changes and FDA Outcomes
Following the End-of-Phase 1 meeting, the FDA selected 80 mg once daily (QD) as the recommended dose for the upcoming Phase 3 ENABLE-2 trial. The trial design is expected to randomize CML patients previously treated with one or more TKIs to receive either ELVN-001 or a physician's choice of an ATP-competitive TKI. Further design details are anticipated following an End-of-Phase 2 meeting in the third quarter of 2026.
Guidance, Risks, and Forward-Looking Statements
The filing contains forward-looking statements regarding the potential efficacy, safety, and commercialization of ELVN-001. Management highlighted risks including the potential for clinical trial results to change, delays in patient enrollment, regulatory disagreements on trial design, and the company's limited resources. The company explicitly notes that no head-to-head trials have been performed, and cross-trial comparisons should be viewed with caution.
Investor Verification Checklist
- Verify the final design and enrollment criteria for the Phase 3 ENABLE-2 trial following the Q3 2026 End-of-Phase 2 meeting.
- Monitor the company's cash runway and capital raising activities, as this 8-K does not disclose current liquidity or burn rate.
- Review the full safety data for the 80 mg QD cohort to assess long-term tolerability compared to the overall population.
- Confirm the timeline for the initiation of the ENABLE-2 Phase 3 trial.
- Assess the competitive landscape for CML treatments, particularly regarding ATP-competitive TKIs used as comparators in the upcoming Phase 3 trial.